Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism

Eur Neuropsychopharmacol. 2014 Jan;24(1):160-71. doi: 10.1016/j.euroneuro.2013.07.001. Epub 2013 Aug 2.

Abstract

We previously reported that the investigational multimodal antidepressant, vortioxetine, reversed 5-HT depletion-induced memory deficits while escitalopram and duloxetine did not. The present report studied the effects of vortioxetine and the potential impact of its 5-HT1A receptor agonist and 5-HT3 receptor antagonist properties on 5-HT depletion-induced memory deficits. Recognition and spatial working memory were assessed in the object recognition (OR) and Y-maze spontaneous alternation (SA) tests, respectively. 5-HT depletion was induced in female Long-Evans rats using 4-cholro-DL-phenylalanine methyl ester HCl (PCPA) and receptor occupancies were determined by ex vivo autoradiography. Rats were acutely dosed with vortioxetine, ondansetron (5-HT3 receptor antagonist) or flesinoxan (5-HT1A receptor agonist). The effects of chronic vortioxetine administration on 5-HT depletion-induced memory deficits were also assessed. 5-HT depletion reliably impaired memory performance in both the tests. Vortioxetine reversed PCPA-induced memory deficits dose-dependently with a minimal effective dose (MED) ≤0.1mg/kg (∼80% 5-HT3 receptor occupancy; OR) and ≤3.0mg/kg (5-HT1A, 5-HT1B, 5-HT3 receptor occupancy: ∼15%, 60%, 95%) in SA. Ondansetron exhibited a MED ≤3.0μg/kg (∼25% 5-HT3 receptor occupancy; OR), but was inactive in the SA test. Flesinoxan had a MED ≤1.0mg/kg (∼25% 5-HT1A receptor occupancy; SA); only 1.0mg/kg ameliorated deficits in the NOR. Chronic p.o. vortioxetine administration significantly improved memory performance in OR and occupied 95%, 66%, and 9.5% of 5-HT3, 5-HT1B, and 5-HT1A receptors, respectively. Vortioxetine's effects on SA performance may involve 5-HT1A receptor agonism, but not 5-HT3 receptor antagonism, whereas the effects on OR performance may involve 5-HT3 receptor antagonism and 5-HT1A receptor agonism.

Keywords: 5-HT depletion; 5-HT(1A) receptor; 5-HT(3) receptor; Cognitive dysfunction; Major depressive disorder; Vortioxetine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8-Hydroxy-2-(di-n-propylamino)tetralin / pharmacokinetics
  • Animals
  • Benzamides / pharmacokinetics
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Female
  • Indazoles / pharmacokinetics
  • Maze Learning / drug effects
  • Memory Disorders / chemically induced
  • Memory Disorders / drug therapy*
  • Memory, Short-Term / drug effects*
  • Phenylalanine / analogs & derivatives
  • Phenylalanine / pharmacology
  • Piperazines / therapeutic use*
  • Protein Binding / drug effects
  • Pyridines / pharmacokinetics
  • Rats
  • Rats, Long-Evans
  • Receptor, Serotonin, 5-HT1A / metabolism
  • Receptors, Serotonin, 5-HT3 / metabolism
  • Recognition, Psychology / drug effects*
  • Serotonin 5-HT1 Receptor Agonists / therapeutic use*
  • Serotonin 5-HT3 Receptor Antagonists / therapeutic use*
  • Sulfides / therapeutic use*
  • Time Factors
  • Tritium / pharmacokinetics
  • Tropanes / pharmacokinetics
  • Vortioxetine

Substances

  • Benzamides
  • Indazoles
  • N-(4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)-3-methyl-4-(4-pyridyl)benzamide
  • Piperazines
  • Pyridines
  • Receptors, Serotonin, 5-HT3
  • Serotonin 5-HT1 Receptor Agonists
  • Serotonin 5-HT3 Receptor Antagonists
  • Sulfides
  • Tropanes
  • Tritium
  • Receptor, Serotonin, 5-HT1A
  • LY 278584
  • phenylalanine methyl ester
  • Vortioxetine
  • Phenylalanine
  • 8-Hydroxy-2-(di-n-propylamino)tetralin